耐火性纯红细胞无形成症与T细胞大粒状淋巴细胞白血病相关,由ruxolitinib治疗
Yuemin Gong1, Yue Li1, Xiaoyu Chen1
1Department of Hematology, Jiangsu Province Hospital, Key Laboratory of Hematology, Collaborative Innovation Center for Cancer Personalized Medicine, The First Affiliated Hospital, Nanjing Medical University, No. 300 Guangzhou Road, Nanjing, 210000, China.
Annals of hematology
|June 27, 2024
概括
与T细胞大颗粒性淋巴细胞 (T-LGL) 白血病相关的耐火性获得的纯红细胞无形成症 (PRCA) 可以通过ruxolitinib有效治疗. 这种JAK抑制剂导致了对其他疗法的耐药性患者的完全缓解.
科学领域:
- 血液学 血液学 血液学
- 在瘤学瘤学.
- 免疫学 免疫学 免疫学
背景情况:
- 获得的纯红细胞无血症 (PRCA) 是一种罕见的贫血.
- 耐火性PRCA带来了治疗挑战,特别是当与T细胞大粒状淋巴细胞 (T-LGL) 白血病相关时.
- T细胞大颗粒性淋巴细胞白血病涉及JAK-STAT通路的激活.
更多相关视频
12:36Single-cell Analysis of Immunophenotype and Cytokine Production in Peripheral Whole Blood via Mass Cytometry
Published on: June 26, 2018
9.4K
09:34Dynamic Imaging of Chimeric Antigen Receptor T Cells with [18F]Tetrafluoroborate Positron Emission Tomography/Computed Tomography
Published on: February 17, 2022
3.3K
